The United States is approaching a critical public health milestone for the wrong reasons: after maintaining measles elimination status for more than a quarter-century, the country is at risk of losing that designation because sustained transmission of the virus has continued for more than 12 months. Public health authorities and independent experts say the determination will depend on whether international health officials conclude that uninterrupted domestic spread has met the criteria for the disease to be considered re-established rather than repeatedly imported.
The development is significant because "elimination" does not mean measles has disappeared. The United States achieved elimination status in 2000 after decades of widespread vaccination and strong disease surveillance. Under standards used by the World Health Organization and the Pan American Health Organization (PAHO), elimination means there has been no continuous endemic transmission of the same measles virus chain for at least 12 months. Imported cases remain expected in a globalized world, but public health systems are expected to contain them before prolonged community spread occurs. Losing that designation would therefore indicate not simply an increase in cases but a breakdown in the country's ability to consistently interrupt transmission.
The current situation reflects trends that have intensified over several years. According to the U.S. Centers for Disease Control and Prevention (CDC), national measles, mumps and rubella (MMR) vaccination coverage among kindergarten children has declined from above the 95% level generally associated with community immunity to about 92.5% in the 2024-2025 school year. The CDC estimates that this has left roughly 286,000 kindergarteners insufficiently protected. While national averages remain relatively high, health officials emphasize that vaccination coverage varies substantially across communities, allowing clusters of susceptible individuals to develop even in states with otherwise strong immunization rates.
Those immunity gaps have coincided with a sharp increase in outbreaks. CDC data show that measles activity accelerated during 2025 and remained elevated throughout 2026, with confirmed cases spreading across dozens of jurisdictions. The agency has attributed the resurgence primarily to declining vaccination coverage combined with imported infections that found communities where transmission could continue.
Scientists and epidemiologists note that measles is uniquely sensitive to even modest declines in vaccine uptake because it is among the world's most contagious infectious diseases. Two doses of the MMR vaccine provide approximately 97% protection against measles, according to the CDC. Because the virus spreads so efficiently through respiratory droplets and can remain infectious in the air after an infected person leaves an area, maintaining high vaccination coverage is considered essential to preventing outbreaks.
The resurgence also illustrates broader challenges facing public health systems following the COVID-19 pandemic. Routine childhood immunization rates declined in several countries during and after the pandemic because of healthcare disruptions, delayed preventive care, and growing vaccine hesitancy. U.S. public health experts have also pointed to misinformation, declining confidence in vaccines in some communities, and uneven access to preventive healthcare as contributing factors. While experts differ in their emphasis on these drivers, they broadly agree that reduced vaccination coverage has increased the likelihood that imported measles cases can spark sustained outbreaks.
Historically, the United States has experienced significant measles outbreaks since elimination was declared, most notably in 2019, when more than 1,200 cases were reported. Those outbreaks, however, were ultimately contained before they met the threshold for continuous endemic transmission. The present situation differs because epidemiological investigations suggest that related chains of transmission may have persisted long enough to trigger formal review of the country's elimination status. Final determination depends not only on case numbers but also on laboratory surveillance and genetic evidence demonstrating whether transmission has remained uninterrupted.
Losing elimination status would not immediately change clinical treatment, vaccine recommendations or international travel policies. Instead, its primary importance would be epidemiological and symbolic. It would signal that a disease once considered under sustained control has regained the ability to circulate domestically despite the availability of a highly effective vaccine. Public health agencies would continue emphasizing vaccination, surveillance, rapid case identification and outbreak response as the principal tools for limiting transmission and eventually restoring elimination status.
The coming review by regional public health authorities will therefore focus less on the total number of infections than on whether available evidence demonstrates more than a year of uninterrupted transmission from a single chain of infection. Until that assessment is completed, officials continue monitoring outbreak investigations, vaccination coverage and laboratory surveillance while seeking to interrupt remaining transmission through established public health measures.
